Skip to main content

Table 4 Predictive factors for 2-year disease-free survival rate and grade III or IV toxicity in patients with gastric cancer who underwent adjuvant TS-1 treatment

From: Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment

Variables

2-year disease-free survival rate

P

Grade III or IV toxicity n (%)

P

Gender

Male (n = 24)

75%

0.68

6 (25.0)

0.33

Female (n = 16)

74%

2 (12.5)

Age

≥65 (n = 13)

82%

0.29

1 (7.7)

0.18

<65 (n = 27)

50%

7 (25.9)

Histological type

Diffuse type (n = 25)

74%

0.57

6 (24.0)

0.41

Intestinal type (n = 15)

75%

2 (13.3)

ECOG performance status scale

0 (n = 32)

74%

0.63

6 (18.8)

0.74

1 to 2 (n = 8)

75%

2 (25.0)

Type of gastrectomy

Total (n = 15)

72%

0.66

6 (40.0)

0.014

Subtotal (n = 25)

76%

2 (8.0)

T stage

1 to 2 (n = 28)

82%

0.44

6 (21.4)

0.73

3 to 4 (n = 12)

75%

2 (16.7)

Lymph node metastases numbers

0 to 15 (n = 34)

91%

<0.001

0 (0)

0.18

>15 (n = 6)

17%

(HR 0.09, 95% CI 0.02, 0.40)

8 (23.5)

  1. CI: confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio.